secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2026-05-13T20:04:40+00:00
Accession:  0001398733-26-000029
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 1.02, 2.02, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive Q1 revenue up 66% to $14.4M; secures $150M Oaktree debt facility
--------------------------------------------------------------------------

- Q1 total revenue $14.4M (+66% YoY); license/royalty $5.4M, manufacture/supply $8.8M.
- R&D expenses down to $4.2M from $5.4M; SG&A $11.0M vs $19.1M (prior year included $4.3M PDUFA fee).
- Reaffirmed Anaphylm NDA resubmission in Q3 2026 after FDA Type A meeting alignment on studies.
- Entered $150M Oaktree debt facility: $55M funded, $20M available on FDA approval, $25M on sales milestone.
- Used proceeds to repay $45M existing notes; expects $150M cash for Anaphylm launch if approved in 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000139873326000029/0001398733-26-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000139873326000029/aqst-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001398733-26-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer